Skip to content
Menu

Attovia Therapeutics, Inc. ATTO

Full chart Compare
Set alert

Price alert · ATTO

All alert types
15.58 USD +0.05 (+0.32%)

Regular-session close

15.58 0.00 0.00%

After hours · Nov 19, 4:00 PM ET

15.19 Day range 16.58
12.94 52-week range 28.00
YTD
-28.86%
1 year
-28.86%

5D -2.11 (-12.52%)

14151617WedThuFriMonTue14.74
Market cap
712.20M
Revenue (ttm)
1.80M
EPS (ttm)
-5.53
Shares out
45.65M
Forward P/E
-9.30
YTD return
-28.86%
1-year return
-28.86%
50-day average
21.62
Volume
159.31K
Avg volume
337.11K
Open
15.19
Previous close
15.53
Day's range
15.19 – 16.58
52-week range
12.94 – 28.00
Analysts
Strong Buy
Price target
42.20 (+170.9%)

Key statistics

200-day average
21.62
Enterprise value
1.19B
Price / sales
561.51
Total cash
115.13M
Total debt
4.33M

Fundamental scorecard

3 of 25 checks passed on ATTO’s reported financials

ValueGrowthProfitabilityHealthDividend

3of 25 checks passed

  • Value 0 of 5
  • Growth No data
  • Profitability No data
  • Financial health 3 of 5
  • Dividend No data

Statements to Sep 30, 2026.

Financials — quick view

All financials
ATTO Revenue — quarterly 0
ATTO Net income — quarterly -22.74M
ATTO EPS — quarterly -0.76

Earnings

ATTO recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Sep 2, 2026Jun 30, 2026-0.6459-4.88-4.23-655.53%

Upgrades / downgrades

ATTO analyst upgrades and downgrades
DateFirmActionFromTo
Aug 31, 2026Citigroupinit—Buy
Aug 31, 2026LifeSci Capitalinit—Outperform
Aug 31, 2026Leerink Partnersinit—Outperform
Aug 31, 2026RBC Capitalinit—Outperform
Aug 31, 2026Morgan Stanleyinit—Overweight

About Attovia Therapeutics, Inc.

Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. The company's products include ATTO-1310, a novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31; developed for the treatment of chronic pruritic diseases such as CPUO, high-itch AD, cholestatic pruritus, and CKD-aP; ATTO-2306, an ATTOBODY-based, half-life-extended immunoglobulin G (IgG)-fusion protein therapeutic that inhibits IL-13 and IL-31; developed for the treatment of AD and other immune-mediated skin diseases, such as CSU and PN; and ATTO-1091, a trispecific ATTOBODY-based Fc-fusion protein therapeutic that inhibits TL1A, IL-23, and integrin a4ß7; developed for IBD a chronic immune-mediated condition characterized by persistent inflammation of the gastrointestinal tract, includes ulcerative colitis (UC) and crohn's disease (CD). The company was incorporated in 2022 and is based in San Carlos, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
attovia.com

News

Your note

Sign in to keep a note on ATTO — it syncs with the Stock Master app.

Insider holders

ATTO insider holders
InsiderRelationLatest transactionDateShares held
DEEP TRACK BIOTECHNOLOGY MASTER FUND LTDBeneficial Owner of more than 10% of a Class of SecurityConversion of Exercise of derivative securityAug 5, 20260
FRAZIER LIFE SCIENCES X, L.P.Beneficial Owner of more than 10% of a Class of SecurityPurchaseAug 5, 20260
FRAZIER LIFE SCIENCES XI , L.P.Beneficial Owner of more than 10% of a Class of SecurityPurchaseAug 5, 20260
GOLDMAN SACHS GROUP INC.UnknownPurchaseAug 5, 20260
GOLDMAN SACHS GROUP, INC.Beneficial Owner of more than 10% of a Class of SecurityPurchaseAug 5, 20260
REDMILE GROUP, L.L.C.Beneficial Owner of more than 10% of a Class of SecurityPurchaseAug 5, 20260